Insider Selling: Editas Medicine (NASDAQ:EDIT) EVP Sells $18,909.88 in Stock

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) EVP Linda Burkly sold 7,814 shares of the firm’s stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $2.42, for a total transaction of $18,909.88. Following the sale, the executive vice president owned 70,379 shares in the company, valued at approximately $170,317.18. The trade was a 9.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Linda Burkly also recently made the following trade(s):

  • On Thursday, September 3rd, Linda Burkly sold 709 shares of Editas Medicine stock. The shares were sold at an average price of $3.04, for a total transaction of $2,155.36.

Editas Medicine Stock Performance

Shares of NASDAQ EDIT opened at $2.17 on Monday. The firm has a market cap of $334.92 million, a PE ratio of -3.50 and a beta of 2.08. Editas Medicine, Inc. has a 1-year low of $1.66 and a 1-year high of $3.94. The company has a fifty day moving average price of $2.63 and a 200 day moving average price of $2.69.

Editas Medicine (NASDAQ:EDIT – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. Editas Medicine had a negative return on equity of 130.43% and a negative net margin of 144.95%. The firm had revenue of $10.37 million during the quarter, compared to analysts’ expectations of $4.46 million. Equities research analysts forecast that Editas Medicine, Inc. will post -0.79 EPS for the current year.

Institutional Investors Weigh In On Editas Medicine

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP bought a new position in shares of Editas Medicine in the 2nd quarter valued at about $1,190,000. Opaleye Management Inc. increased its position in shares of Editas Medicine by 100.4% in the second quarter. Opaleye Management Inc. now owns 3,861,930 shares of the company’s stock valued at $12,513,000 after acquiring an additional 1,934,933 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Editas Medicine in the second quarter valued at about $4,311,000. Renaissance Technologies LLC raised its holdings in Editas Medicine by 30.7% during the first quarter. Renaissance Technologies LLC now owns 3,972,160 shares of the company’s stock worth $9,811,000 after acquiring an additional 932,382 shares in the last quarter. Finally, BlackRock Inc. bought a new stake in Editas Medicine during the second quarter worth about $34,312,000. 71.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

EDIT has been the subject of several recent research reports. Wall Street Zen raised Editas Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Guggenheim raised Editas Medicine from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a research report on Wednesday, September 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Editas Medicine in a research report on Wednesday, November 4th. Wells Fargo & Company upgraded Editas Medicine from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $4.00 to $6.00 in a research note on Thursday, October 8th. Finally, Ladenburg Thalmann & Co. Inc. initiated coverage on Editas Medicine in a research report on Tuesday, August 18th. They set a “buy” rating and a $6.00 price target for the company. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Editas Medicine presently has a consensus rating of “Moderate Buy” and an average price target of $5.83.

Get Our Latest Stock Analysis on Editas Medicine

Editas Medicine Company Profile

(Get Free Report)

Editas Medicine, Inc. is a biotechnology company developing genome-editing medicines for people with serious diseases. Its research uses CRISPR-based technologies, including CRISPR-Cas9 and Cas12a, to make targeted changes to DNA. Founded in 2013 and based in Cambridge, Massachusetts, the company conducts research and clinical development of potential treatments for genetic disorders. Its work has included approaches designed to edit genes in a patient’s cells, either outside the body or directly within the body.

Featured Articles

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.